About Protocadherin gamma-B4
Protocadherin gamma-B4 (PCDHGB4) is a protein
from Homo sapiens identified by UniProt accession
Q9UN71, 923 residues long.
MolForge cross-references it against 0 known binders and
14 disease associations.
Target properties
| Protein name | Protocadherin gamma-B4 |
| UniProt accession | Q9UN71 |
| Gene | PCDHGB4 |
| Organism | Homo sapiens |
| Length | 923 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9UN71-F1 | alphafold | PREDICTED | 75.49 | — |
Amino-acid sequence (923 residues)
MGSGAGELGR AERLPVLFLF LLSLFCPALC EQIRYRIPEE MPKGSVVGNL ATDLGFSVQE LPTRKLRVSS EKPYFTVSAE SGELLVSSRL DREEICGKKP ACALEFEAVA ENPLNFYHVN VEIEDINDHT PKFTQNSFEL QISESAQPGT RFILGSAHDA DIGSNTLQNY QLSPSDHFSL INKEKSDGSK YPEMVLKTPL DREKQKSYHL TLTALDFGAP PLSSTAQIHV LVTDANDNAP VFSQDVYRVS LSENVYPGTT VLQVTATDQD EGVNAEITFS FSEASQITQF DLNSNTGEIT VLNTLDFEEV KEYSIVLEAR DGGGMIAQCT VEVEVIDEND NAPEVIFQSL PNLIMEDAEL GTHIALLKVR DKDSRHNGEV TCKLEGDVPF KILTSSRNTY KLVTDAVLDR EQNPEYNITV TATDRGKPPL SSSSSITLHI GDVNDNAPVF SQSSYIVHVA ENNPPGASIS QVRASDPDLG PNGQVSYCIM ASDLEQRELS SYVSISAESG VVFAQRAFDH EQLRAFELTL QARDQGSPAL SANVSLRVLV DDRNDNAPRV LYPALGPDGS ALFDMVPHAA EPGYLVTKVV AVDADSGHNA WLSYHVLQAS EPGLFSLGLR TGEVRTARAL GDRDAVRQRL LVAVRDGGQP PLSATATLHL VFADSLQEVL PDITDRPDPS DLQAELQFYL VVALALISVL FLVAMILAIA LRLRRSSSPA SWSCFQPGLC VKSESVVPPN YSEGTLPYSY NLCVAHTGKT EFNFLKCSEQ LSSGQDILCG DSSGALFPLC NSSELTSHQQ APPNTDWRFS QAQRPGTSGS QNGDDTGTWP NNQFDTEMLQ AMILASASEA ADGSSTLGGG AGTMGLSARY GPQFTLQHVP DYRQNVYIPG SNATLTNAAG KRDGKAPAGG NGNKKKSGKK EKK
Explore Protocadherin gamma-B4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets